Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer.

Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG.

Front Oncol. 2016 Feb 16;6:24. doi: 10.3389/fonc.2016.00024. eCollection 2016. Review.

2.

Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer.

Wilkins A, Dearnaley D, Somaiah N.

Biomed Res Int. 2015;2015:238757. doi: 10.1155/2015/238757. Epub 2015 Oct 4. Review.

3.

A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.

Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY.

Clin Cancer Res. 2014 Dec 15;20(24):6379-88. doi: 10.1158/1078-0432.CCR-14-0075. Epub 2014 Oct 7.

4.

Prognostic significance of B-cell lymphoma 2 expression in acute leukemia: A systematic review and meta-analysis.

Liu Y, He P, Liu F, Shi L, Zhu H, Cheng X, Zhao J, Wang Y, Zhang M.

Mol Clin Oncol. 2014 May;2(3):411-414. Epub 2014 Jan 24.

5.

Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer.

Albany C, Hahn NM.

Asian J Androl. 2014 May-Jun;16(3):359-63. doi: 10.4103/1008-682X.126400. Review.

6.

Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Sequeiros T, García M, Montes M, Oliván M, Rigau M, Colás E, de Torres I, Morote J, Reventós J, Doll A.

Biomed Res Int. 2013;2013:283635. doi: 10.1155/2013/283635. Epub 2013 Nov 25. Review.

7.

ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells.

Parrondo R, de Las Pozas A, Reiner T, Perez-Stable C.

PeerJ. 2013 Sep 12;1:e144. doi: 10.7717/peerj.144. eCollection 2013.

8.

RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.

Rahman MA, Amin AR, Wang D, Koenig L, Nannapaneni S, Chen Z, Wang Z, Sica G, Deng X, Chen ZG, Shin DM.

Clin Cancer Res. 2013 Jul 1;19(13):3416-28. doi: 10.1158/1078-0432.CCR-13-0073. Epub 2013 May 29.

10.

Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.

Verhoven B, Yan Y, Ritter M, Khor LY, Hammond E, Jones C, Amin M, Bahary JP, Zeitzer K, Pollack A.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):317-23. doi: 10.1016/j.ijrobp.2013.01.016. Epub 2013 Mar 6.

11.

Systematic review of hypofractionated radiation therapy for prostate cancer.

Zaorsky NG, Ohri N, Showalter TN, Dicker AP, Den RB.

Cancer Treat Rev. 2013 Nov;39(7):728-36. doi: 10.1016/j.ctrv.2013.01.008. Epub 2013 Mar 1. Review.

12.

Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers.

Lucas SM, Heath EI.

Prostate Cancer. 2012;2012:640968. doi: 10.1155/2012/640968. Epub 2012 Aug 28.

14.

Tissue biomarkers for prostate cancer radiation therapy.

Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, Wild AT, Kumar R, Herman JM, Song DY, DeWeese TL.

Curr Mol Med. 2012 Jul 1;12(6):772-87. Review.

15.

Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation.

Zeitlin BD, Spalding AC, Campos MS, Ashimori N, Dong Z, Wang S, Lawrence TS, Nör JE.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):879-87. doi: 10.1016/j.ijrobp.2010.04.024. Epub 2010 Aug 1.

16.

The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.

Maximov PY, Lewis-Wambi JS, Jordan VC.

Curr Signal Transduct Ther. 2009 May 1;4(2):88-102.

17.

An improved method for constructing tissue microarrays from prostate needle biopsy specimens.

McCarthy F, Fletcher A, Dennis N, Cummings C, O'Donnell H, Clark J, Flohr P, Vergis R, Jhavar S, Parker C, Cooper CS.

J Clin Pathol. 2009 Aug;62(8):694-8. doi: 10.1136/jcp.2009.065201.

18.

Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?

Rosser CJ, Gaar M, Porvasnik S.

BMC Cancer. 2009 Jul 9;9:225. doi: 10.1186/1471-2407-9-225. Review.

19.

Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells.

Yan M, Hardin K, Ho E.

J Nutr Biochem. 2010 Aug;21(8):687-94. doi: 10.1016/j.jnutbio.2009.04.002. Epub 2009 Jul 2.

20.

Predictive models in external beam radiotherapy for clinically localized prostate cancer.

Roach M 3rd, Waldman F, Pollack A.

Cancer. 2009 Jul 1;115(13 Suppl):3112-20. doi: 10.1002/cncr.24348. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk